Topics

Human medicines European public assessment report (EPAR): Cervarix, human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed), Papillomavirus Infections,Uterine Cervical Dysplasia,Immunization, Date of authorisation: 20/09/2007, Revi

08:36 EDT 4 Jun 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Cervarix, human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed), Papillomavirus Infections,Uterine Cervical Dysplasia,Immunization, Date of authorisation: 20/09/2007, Revision: 32, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Cervarix, human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed), Papillomavirus Infections,Uterine Cervical Dysplasia,Immunization, Date of authorisation: 20/09/2007, Revi

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Cervarix, human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed), Papillomavirus Infections,Uterine Cervical Dysplasia,Immunization, Date of authorisation: 20/09/2007, Revi"

Quick Search

Relevant Topics

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...